Abstract | BACKGROUND: METHOD: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. RESULTS: CONCLUSIONS: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.
|
Authors | Eri Muso, Masatoshi Mune, Tsutomu Hirano, Motoshi Hattori, Kenjiro Kimura, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shunya Uchida, Takashi Wada, Tetsuo Shoji, Yukio Yuzawa, Tsukasa Takemura, Satoshi Sugiyama, Yoshiki Nishizawa, Satoru Ogahara, Noriaki Yorioka, Soichi Sakai, Yosuke Ogura, Susumu Yukawa, Yasuhiko Iino, Enyu Imai, Seiichi Matsuo, Takao Saito |
Journal | Clinical and experimental nephrology
(Clin Exp Nephrol)
Vol. 19
Issue 3
Pg. 379-86
(Jun 2015)
ISSN: 1437-7799 [Electronic] Japan |
PMID | 24934117
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Lipoproteins, LDL
- Serum Albumin
|
Topics |
- Adult
- Aged
- Blood Component Removal
- Drug Resistance
- Female
- Humans
- Hyperlipidemias
(etiology, therapy)
- Hypoproteinemia
(etiology, therapy)
- Lipoproteins, LDL
- Male
- Middle Aged
- Nephrotic Syndrome
(complications, drug therapy, therapy, urine)
- Prospective Studies
- Proteinuria
(etiology, therapy)
- Serum Albumin
(metabolism)
- Time Factors
|